Browse result page of CancerPDF Database

Please click on CancerPDF_ID for detailed information about peptide.

CancerPDF_IDPeptide seqProtein NameFluidMass/ZProfiling TechniqueCancer Type Expression RegulationPUBMED ID
CancerPDF_ID91 RPPGFSPFBradykinin (and des-Arg bradykinin)Serum904.48MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID92 RPPGFSPFRBradykinin (and des-Arg bradykinin)Serum1060.57MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID93 NABradykinin (and des-Arg bradykinin)Serum920.41MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID94 NABradykinin (and des-Arg bradykinin)Serum1076.53MALDI-TOFMetastatic thyroid carcinomas NA 16896061
CancerPDF_ID161 RPPGFSPFBradykininSerum904.4726MALDI-TOF"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy" Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS 19728888
CancerPDF_ID1088 RPPGFSPFBradykinin (and des-Arg bradykinin)Serum904.48MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.06, 0.79 and 1.62 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1089 RPPGFSPFRBradykinin (and des-Arg bradykinin)Serum1060.57MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =0.77, 0.43 and 1.9 in prostate, bladder and breast cancer respectively" 16395409
CancerPDF_ID1090 NABradykinin (and des-Arg bradykinin)Serum920.41MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409
CancerPDF_ID1091 NABradykinin (and des-Arg bradykinin)Serum1076.53MALDI-TOF"Advanced Prostate, Breast and Bladder cancer" NA 16395409